ASH 2024 Annual Meeting
Leaders from the Mass General Cancer Center will present groundbreaking cancer research at this year’s ASH 2024 Annual Meeting, held December 6–10, 2024, both in-person in San Diego, CA, and virtually.
Join 30,000+ health professionals, clinicians, researchers, educators, and more, at the 66th ASH Annual Meeting and Exposition. This year's meeting will once again take place in San Diego, California, and online, December 7-10, 2024. The ASH annual meeting is the world's largest and most comprehensive hematology event of the year. With hundreds of sessions on the hottest trends in hematology, ASH offers multiple ways for attendees to find exactly what they are looking for.
Friday, December 6, 2024
Medical Crossfire®: Bridging Evidence to Practice in AML... Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials
11:00 a.m. – 2:00 p.m. in San Diego Convention Center (SDCC) Ballroom 20CD
Symposia Speaker: Amir T. Fathi, MD
What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma
11:30 a.m. – 1:30 p.m. in Manchester Grand Hyatt San Diego Seaport Ballroom ABCD
Symposia Chair: Jeremy S. Abramson, MD, MMSc
Collaboration in Chronic ITP: Improving Quality of Life and Patient Outcomes
3:00 p.m. – 6:00 p.m. in SDCC Ballroom 20AB
Symposia Speaker: David J. Kuter, MD, DPhil
Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET
3:00 p.m. – 6:00 p.m. in SDCC Ballroom 20CD
Symposia Speaker: Gabriela Hobbs, MD
Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GVHD Prophylaxis, Acute, and Chronic Care?
7:00 p.m. – 10:00 p.m. in SDCC Room 6A
Symposia Speaker: Yi-Bin Chen, MD
Saturday, December 7, 2024
The Expanding Landscape of Treatment for ITP
9:30 a.m. – 10:45 a.m. in SDCC Room 28 A-D
Oral Presentation: Annemarie E. Fogerty, MD
Session 653: Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma
9:30 a.m.
Oral Presentation: Joshua Gustine, MD; Noopur Raje, MD
Session 908: Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy
10:00 a.m.
Oral Presentation: Areej El-Jawahri, MD
Session 330: Special Symposium on the Basic Science of Hemostasis and Thrombosis -- Coagulation Factor XII (F12) Haploinsufficiency is Protective Against Venous Thromboembolism
12:00 p.m.
Oral Presentation: Amelia K. Haj, MD, PhD
Education Program: Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios -- Porphyria Cutanea Tarda: A Unique Iron-Related Disorder
2:00 p.m. – 3:15 p.m. in SDCC Room 29
Oral Presentation: Rebecca Karp Leaf, MD
Education Program: Chasing Zebras: Navigating Rare Myeloid Neoplasms -- The Spectrum of Ph Negative Disease: CNL and CSF3R-Related Disorders
2:00 p.m. – 3:15 p.m. in Manchester Grand Hyatt San Diego Grand Hall C
Oral Presentation: Robert P. Hasserjian, MD
Education Program: Integrating New Therapies into the Management of Classical Heme Disorders
2:00 p.m. – 3:15 p.m. in SDCC Room 30
Oral Presentation: Amy Dickey, MD, MSC
Session 906: Comparison Between Vulnerable Elders Survey-13 and Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas
4:00 p.m. – 5:30 p.m.
Oral Presentation: Patrick Connor Johnson, MD
Session 616: A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS
5:30 p.m. – 7:30 p.m.
Poster: Amir T. Fathi, MD
Session 637: Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy
5:30 p.m. – 7:30 p.m.
Poster: Andrew Brunner, MD
Session 642: Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
5:30 p.m. – 7:30 p.m.
Poster: Jacob Soumerai, MD
Session 905: Pre-Transplant Patient-Reported Outcomes Are Associated with Health Care Utilization and Transplant-Related Complications at One-Year Post-Transplant
5:30 p.m. – 7:30 p.m.
Poster: Anna Barata, PhD
Session 603: Integrative Analysis of 3D Chromatin Organization Revealed Regulation Mechanisms in Angioimmunoblastic T-Cell Lymphoma
5:30 p.m. – 7:30 p.m.
Poster: Makoto Iwasaki, MD, PhD; Salvia Jain, MD
Special Interest Session: Hematology Inclusion Pathway (HIP) Oral Presentations - Malignant Hematology -- Identifying Mechanisms of Resistance to ATR Inhibition in Myelodysplastic Syndromes with Splicing Factor Mutations
6:00 p.m. – 9:00 p.m. in Marriott Marquis San Diego Marina Ballroom D
Oral Presentation: Catherine Gutierrez, MD, PhD
Sunday, December 8, 2024
Joint Session: Therapeutic Gene Editing of Stem Cells in Classical and Malignant Hematology
9:30 a.m. – 11:05 a.m. in SDCC Room 29
Chair: Marcela V. Maus, MD, PhD
Session 624: Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
10:15 a.m. – 10:30 a.m. in SDCC Ballroom 20AB
Oral Presentation: Jeremy S. Abramson, MD, MMSc
Plenary Scientific Session: Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3)
2:00 p.m. – 4:00 p.m.
Oral Presentation: David J. Kuter, MD, DPhil
Session 605: Activity of Orally Available CBP/p300 Degraders in Pre-Clinical Models of Multiple Myeloma
6:00 p.m. – 8:00 p.m.
Poster: Christopher J. Ott, PhD
Session 616: Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007
6:00 p.m. – 8:00 p.m.
Poster: Amir T. Fathi, MD
Session: 622: Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics
6:00 p.m. – 8:00 p.m.
Poster: Dimitra Karagkouni, PhD; Salvia Jain, MD
Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
6:00 p.m. – 8:00 p.m.
Poster: Jeremy S. Abramson, MD, MMSc
Session 653: Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma
6:00 p.m. – 8:00 p.m.
Poster: Noopur Raje, MD; Farah Rexha, BS
Monday, December 9, 2024
Session 311: A Phase 2 Study of Ianalumab in Patients with Primary Immune Thrombocytopenia Previously Treated with at Least Two Lines of Therapy: Interim Results from VAYHIT3
10:45 a.m.
Oral Presentation: David J. Kuter, MD, DPhil
Trainee Didactic Session: Setting up a Health Services and Outcomes Research Program
12:15 p.m. – 1:15 p.m. in SDCC Room 31
Oral Presentation: Areej El-Jawahri, MD
Special Interest Session: ASH Quality Improvement Champions
2:45 p.m. – 4:15 p.m. in SDCC Room 7
Chair: Rachel P. Rosovsky, MD
Session 637: Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia
4:30 p.m. – 6:30 p.m. in Manchester Grand Hyatt San Diego Grand Hall D
Moderator: Andrew Brunner, MD
Session 642: Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101
5:15 p.m.
Oral Presentation: Jacob Soumerai, MD
Session 617: Real-World Treatment Patterns and Effectiveness of Midostaurin Versus Quizartinib in FLT3-ITD Mutated Acute Myeloid Leukemia Undergoing Intensive Induction
6:00 p.m. – 8:00 p.m.
Poster: Michelle Hyunju Lee, MD; Amir T. Fathi, MD
Session 634: Risk of Osteoporosis and Osteoporotic Fractures in Patients with Myeloproliferative Neoplasms
6:00 p.m. – 8:00 p.m.
Poster: Michelle Lee, MD; Gabriela Hobbs, MD
Session 631: Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational -- Clinical Features and Preliminary Investigation of PPM1D-Mutated Myeloproliferative Neoplasms
6:00 p.m. – 8:00 p.m. in SDCC Halls G-H
Poster: Hatem Ellaithy, MD
Session 632: A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy
6:00 p.m. – 8:00 p.m.
Poster: Valentina Nardi, MD
Session 903: Impact of Ultra Rapid Molecular Profiling on Treatment Delays and Healthcare Utilization of Patients Hospitalized for Acute Leukemia
6:00 p.m. – 8:00 p.m.
Poster: Tejas Dhawale, MD; Amir T. Fathi, MD
Session 903: Factors Associated with Early Quality of Life Response to Palliative Care During Hematopoietic Stem Cell Transplantation
6:00 p.m. – 8:00 p.m.
Poster: Richard Newcomb, MD
Session 625: Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas
6:00 p.m. – 8:00 p.m.
Poster: Josie G. Ford, BSc; Salvia Jain, MD
